OBJECTIVES Greece is under a very tough and strict memorandum enforced by the European Union that has designed and applied austerity measures in order to save Greek economy and minimizes its public debt. Also the Greek Heath care system should be improved, upgraded or redesigned from scratch in order to be more flexible and more efficient. The legislative intervention made by the European Union and the memorandum in Greek Heath Care system and the Pharmaceutical market constituted legislative framework for the Greek Heath Care and the Pharmaceutical sector. METHODS Data on total pharmaceutical expenditures from 2009-2011, some of them until 2012 were obtained from Hellenic Association of Pharmaceutical Companies. They were analyzed using basic statistical methods of observing.  RESULTS In nearly all observed parameters was recorded their lowering. Total pharmaceutical expenditures per capita Dx= -20%, x=5.073 mil €, pharmaceutical expenditure as % of health expenditure Dx= -6,5%, x=24,1%, pharmaceutical expenditure as % of GDP Dx= -11,1%, x= 2,4%, private pharmaceutical expenditure Dx= -13%, x= 1.094 mil €, private pharmaceutical expenditure per capita Dx= -13,5%, x= 96 €, public pharmaceutical expenditure Dx= -36,8%, x=3.215 €, public pharmaceutical expenditure per capita Dx= -37,6%, x=282 €,  rebate from pharmaceutical companies Dx= +